文献速递前列腺癌

达罗他胺对局部症状的影响:ARAMIS试验的预设和事后分析

Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial.
PubMed 文献 · BJU Int · 2022-09-29

基于III期ARAMIS试验,非转移性去势抵抗性前列腺癌患者按2:1随机接受达罗他胺(n=955)或安慰剂(n=554)。达罗他胺组侵入性操作更少(4.7% vs 9.6%),首次操作时间延长(HR 0.42,95%CI 0.28-0.62),并显著延迟泌尿和肠道症状相关生活质量恶化(P<0.01),泌尿和肠道不良事件发生率与安慰剂相似。

要点

  • 达罗他胺组4.7% vs 安慰剂组9.6%接受侵入性操作,首次操作时间延长(HR 0.42,95%CI 0.28-0.62)。
  • 达罗他胺显著延迟总泌尿和肠道症状生活质量恶化(P<0.01),主要归因于尿频、相关疼痛和日常活动干扰。
  • 达罗他胺治疗患者中PSA反应越好,尿潴留和排尿困难发生率越低。

核心结论

  • 达罗他胺对非转移性去势抵抗性前列腺癌患者的局部疾病复发和症状控制有积极影响,延迟泌尿和肠道症状相关生活质量恶化,且泌尿和肠道相关不良事件发生率与安慰剂相似。

研究设计与样本

  • III期ARAMIS试验(NCT02200614)的预设和事后分析,非转移性去势抵抗性前列腺癌患者按2:1随机接受达罗他胺(n=955)或安慰剂(n=554)。

主要发现

  • 达罗他胺组4.7% vs 安慰剂组9.6%接受前列腺癌相关侵入性操作,达罗他胺组首次操作时间延长(HR 0.42,95%CI 0.28-0.62)。
  • 达罗他胺较安慰剂显著延迟总泌尿和肠道症状生活质量恶化(P<0.01),主要归因于尿频、相关疼痛和日常活动干扰等症状。
  • 达罗他胺组尿潴留和排尿困难不良事件较安慰剂组更少。
  • 达罗他胺治疗患者中PSA反应≥90%、≥50%且<90%、<50%者尿潴留发生率分别为2.2%、4.2%、5.1%,排尿困难发生率分别为0.5%、3.2%、5.1%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess, the effect of darolutamide (a structurally distinct androgen receptor inhibitor) on urinary and bowel symptoms, using data from the phase III ARAMIS trial (NCT02200614) that showed darolutamide significantly reduced the risk of metastasis and death versus placebo. PATIENTS AND METHODS: Patients with non-metastatic castration-resistant prostate cancer (nmCRPC) were randomised 2:1 to darolutamide (n = 955) or placebo (n = 554). Local symptom control was assessed by first prostate cancer-related invasive procedures and post hoc analyses of time to deterioration in quality of life (QoL) using total urinary and bowel symptoms, and individual questions for these symptoms from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Prostate Cancer Module subscales and Functional Assessment of Cancer Therapy-Prostate prostate cancer subscale. Prostate-specific antigen (PSA) responses were correlated with urinary and bowel adverse events (AEs). RESULTS: Fewer patients receiving darolutamide (4.7%) versus placebo (9.6%) underwent invasive procedures, and time to first procedure was prolonged with darolutamide (hazard ratio 0.42, 95% confidence interval 0.28-0.62). Darolutamide significantly (P < 0.01) delayed worsening of QoL for total urinary and bowel symptoms versus placebo, mostly attributed by individual symptoms of urinary frequency, associated pain, and interference with daily activities. AEs of urinary retention and dysuria were less frequent with darolutamide, and greater PSA response (≥90%, ≥50% and <90%, <50%) among darolutamide-treated patients was associated with lower incidences of urinary retention (2.2%, 4.2%, 5.1%) and dysuria (0.5%, 3.2%, 5.1%), respectively. CONCLUSIONS: Darolutamide demonstrated a positive impact on local disease recurrence and symptom control in patients with nmCRPC, delayed time to deterioration in QoL related to urinary and bowel symptoms, and a favourable safety profile showing similar incidence of urinary- and bowel-related AEs compared with placebo.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Shore ND, Stenzl A, Pieczonka C, et al. Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial. BJU Int. 2022. PMID: 36087070. doi:10.1111/bju.15887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。